News Releases

<< Back
Dermira to Host Analyst & Investor Day on May 24, 2018

MENLO PARK, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will host a live webcast in conjunction with its Analyst & Investor Day to be held in New York City on Thursday May 24, 2018 from 8:30 a.m. ET and 11:30 a.m.

The event will include an overview of hyperhidrosis and atopic dermatitis and the current treatment landscapes, the market opportunity and commercial plans for glycopyrronium tosylate, and the lebrikizumab development program.

Dermira Chairman and CEO, Tom Wiggans, will be joined by members of the Dermira management team and leading dermatologists, Dee Anna Glaser, M.D., Professor & Interim Chair, Department of Dermatology, Saint Louis University and Amy S. Paller, M.D., Professor & Chair, Department of Dermatology, Northwestern University.

To view and listen to the webcast, please visit Dermira’s website at http://investor.dermira.com. Visitors will also be able to view and listen to an archive of the webcast found in the Investor Relations section of www.dermira.com. An archive will be available for 30 days following the event.

For registration and more information on the Analyst & Investor Day please refer to the contact information within this press release.

About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif.  For more information, please visit http://www.dermira.com. Follow Dermira on Twitter and LinkedIn.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc-) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Contacts:

Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
erica.jefferson@dermira.com

Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
investor@dermira.com

Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
robert.uhl@westwicke.com

Primary Logo

Source: Dermira, Inc.